Last week, Invitae launched its Non-Invasive Prenatal Screening test while Myriad expanded its Prequel Prenatal Screen to cover all aneuploidies.
Organically, the diagnostics segment was up 14 percent. Overall, the company's revenues grew 18 percent year over year during the quarter.
Illumina said this week that the US Food and Drug Administration has granted breakthrough device designation for its pan-cancer assay, which is currently in development.
Among the updates provided Wednesday, Quidel's CEO noted the firm's growing presence in point-of-care markets, while PerkinElmer discussed plans for its Vanadis test.
The company and Women & Infants Hospital of Rhode Island are currently evaluating the technology to determine the performance of the test.
The FDA cleared LabCorp's assay for quantitative determination of total cholesterol, high density lipoprotein cholesterol, triglycerides, and apolipoprotein B.
Precipio said that its ICE COLD-PCR reagents will be sold with PerkinElmer's DNA/RNA extraction and isolation products.
The firm missed the Wall Street estimates on the top and bottom lines, and it lowered its EPS and adjusted EPS guidance for full-year 2018.
The Lantern Project will screen for patients who may be suffering from Gaucher disease, Fabry disease, Pompe disease, MPS I, or ASMD, and offer confirmatory DNA testing.
The IVD kit is for use with a mass spectrometer and quantitatively measures and evaluates traditionally screened amino acids and measures up to 51 analytes.